# Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

> **NCT01860976** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 489 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01860976
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-17
- **Primary completion:** 2015-07-14
- **Final completion:** 2020-06-30
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01860976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01860976, "Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01860976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*